RSS feed

Publications by Bente K. Kilhovd

27 publications found

Original articles

Skafjeld A, Iversen MM, Holme I, Ribu L, Hvaal K, Kilhovd BK (2015)
A pilot study testing the feasibility of skin temperature monitoring to reduce recurrent foot ulcers in patients with diabetes--a randomized controlled trial
BMC Endocr Disord, 15, 55
DOI 10.1186/s12902-015-0054-x, PubMed 26452544

Lund T, Svindland A, Pepaj M, Jensen AB, Berg JP, Kilhovd B, Hanssen KF (2011)
Fibrin(ogen) may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans
Diab Vasc Dis Res, 8 (4), 284-94
DOI 10.1177/1479164111416831, PubMed 21844128

Granas AG, Berg C, Hjellvik V, Haukereid C, Kronstad A, Blix HS, Kilhovd B, Viktil KK, Horn AM (2010)
Evaluating categorisation and clinical relevance of drug-related problems in medication reviews
Pharm World Sci, 32 (3), 394-403
DOI 10.1007/s11096-010-9385-x, PubMed 20407926

Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Hanssen KF, Laakso M (2009)
Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women
Atherosclerosis, 205 (2), 590-4
DOI 10.1016/j.atherosclerosis.2008.12.041, PubMed 19185865

Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP (2009)
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Vasc Health Risk Manag, 5 (1), 121-8
PubMed 19436668

Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Hanssen KF, Laakso M (2007)
Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study
Diabetologia, 50 (7), 1409-17
DOI 10.1007/s00125-007-0687-z, PubMed 17479244

Fosmark DS, Torjesen PA, Kilhovd BK, Berg TJ, Sandvik L, Hanssen KF, Agardh CD, Agardh E (2006)
Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus
Metabolism, 55 (2), 232-6
DOI 10.1016/j.metabol.2005.08.017, PubMed 16423631

Mentink CJ, Kilhovd BK, Rondas-Colbers GJ, Torjesen PA, Wolffenbuttel BH (2006)
Time course of specific AGEs during optimised glycaemic control in type 2 diabetes
Neth J Med, 64 (1), 10-6
PubMed 16421436

Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF, Laakso M (2005)
High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study
Arterioscler Thromb Vasc Biol, 25 (4), 815-20
DOI 10.1161/01.ATV.0000158380.44231.fe, PubMed 15692098

Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF (2003)
Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes
Metabolism, 52 (2), 163-7
DOI 10.1053/meta.2003.50035, PubMed 12601626

Birkeland KI, Kilhovd B, Thorsby P, Torjesen PA, Ganss R, Vaaler S, Hanssen KF (2003)
Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, beta-cell function and cardiovascular risk profile
Diabet Med, 20 (1), 37-45
DOI 10.1046/j.1464-5491.2003.00838.x, PubMed 12519318

Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A, Scandinavian Repaglinide Group (2001)
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study
Diabet Med, 18 (5), 395-401
DOI 10.1046/j.1464-5491.2001.00490.x, PubMed 11472451

Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999)
Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease
Diabetes Care, 22 (9), 1543-8
DOI 10.2337/diacare.22.9.1543, PubMed 10480523

Landmark K, Abdelnoor M, Urdal P, Kilhovd B, Dørum HP, Borge N, Refvem H (1998)
Use of fish oils appears to reduce infarct size as estimated from peak creatine kinase and lactate dehydrogenase activities
Cardiology, 89 (2), 94-102
DOI 10.1159/000006763, PubMed 9524009

Landmark K, Abdelnoor M, Kilhovd B, Dørum HP (1998)
Eating fish may reduce infarct size and the occurrence of Q wave infarcts
Eur J Clin Nutr, 52 (1), 40-4
DOI 10.1038/sj.ejcn.1600510, PubMed 9481531

Landmark K, Abdelnoor M, Kilhovd B, Dørum HP (1997)
Infarct size as estimated from peak creatine kinase and lactate dehydrogenase is probably reduced in patients using calcium antagonists at the onset of symptoms
Cardiovasc Drugs Ther, 11 (4), 557-65
DOI 10.1023/a:1007727518684, PubMed 9358960

Review articles

Thorsby P, Kilhovd B, Sletmo R, Martinsen S, Birkeland KI (2000)
[Hypoglycemic treatment of type 2 diabetes]
Tidsskr Nor Laegeforen, 120 (20), 2434-40
PubMed 11475233

Book chapters

Birkeland KI, Kilhovd BK, Thorsby P, Torjesen PA, Ganss R, Vaaler S, Hanssen KF (2003)
Heterogeneity of non-insulin-dependent diabetes expressedas variability in insulin sensitivity, beta-cell function and cardiovascular risk profile
In Diabetic medicine, John Wiley, Chichester, 20(2003)1, s.37-45
BIBSYS 04170732x

Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF (2003)
Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes
In Metabolism, Grune & Stratton, New York, 52(2003)2, s.163-7
BIBSYS 041719271

Kilhovd BK, Hjerkinn EM, Seljeflot I, Reikvam AA (2003)
Angiotensin-converting enzyme inhibition influences serumlevels of advanced glycation end products in patients with coronary heart disease: results from a HOPE substudy
In HeartDrug : excellence in cardiovascular trials, Karger, Basel, 3(2003)2, s.67-72
BIBSYS 041719298

Kilhovd B, Hjerkinn EM, Seljeflot I, Berg TJ, Reikvam Å (2001)
Increase in serum levels of advanced glycation endproducts in high risk coronary artery disease patients is modified by the ace inhibitor ramipril
In Diabetologia, Springer, Berlin, 44(2001)suppl 1, s.A319 Abstrakt nr 1226
BIBSYS 02203529x

Thorsby P, Kilhovd B, Birkeland KI (2001)
A single measurement of HBA1c or fasting blood glucose inthe early phase of type 2 diabetes predict long term glycaemic control
In Diabetologia, Springer, Berlin, 44(2001)suppl 1, s.A229 Abstrakt nr 880
BIBSYS 022035729

Kilhovd B, Hjerkinn EM, Seljeflot I, Berg TJ, Reikvam AA (2001)
The ACE inhibitor ramipril influences the serum levels ofadvanced glycation endproducts in high risk patients with coronary artery disease: results from a HOPE substudy
In European heart journal, Supplements, Saunders, London, 22(2001)Abstr. suppl, s.27 Abstrakt nr 243
BIBSYS 022034269

Thorsby P, Kilhovd B, Sletmo R, Martinsen S, Birkeland KI (2000)
Blodsukkersenkende behandling ved type 2-diabetes
In Tidsskrift for Den norske legeforening, Foreningen, Oslo, 120(2000)nr. 20, S. 2434-2440
BIBSYS 010831576

Kilhovd B, Giardino I, Torjesen PA, Birkeland KI, Thornalley PJ, Brownlee M, Hanssen KF (2000)
Increased serum methylglyoxal-derived hydroimidazolone inpatients with type 2 diabetes
In European journal of endocrinology, Supplementum, BioScientifica Ltd., Bristol, 142(2000)Suppl 1, s.26
BIBSYS 010890785

Kilhovd B, Giardino I, Torjesen PA, Birkeland KI, Thornalley PJ, Brownlee M, Hanssen KF (2000)
Increased serum methylglyoxal-derived hydroimidazolone inpatients with type 2 diabetes
In Diabetologia, Springer, Berlin, 43(2000)Suppl.1, s.A53 210
BIBSYS 01078408x

Theses

Kilhovd BK (2004)
Advanced glycation end products (AGEs) and atherosclerotic vascular disease
Faculty of Medicine, [University of Oslo], Oslo, 1 b. (flere pag.)
BIBSYS 041369246, ISBN 82-8080-086-7